Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

IND Swift Laboratories Ltd (ISLB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
124.90 +0.49    +0.39%
26/04 - Closed. Currency in INR ( Disclaimer )
  • Volume: 48,759
  • Bid/Ask: 124.25 / 125.00
  • Day's Range: 123.49 - 128.00
Type:  Equity
Market:  India
ISIN:  INE915B01019 
S/N:  INDSWFTLAB
Ind-Swift Labs 124.90 +0.49 +0.39%

Ind-Swift Labs Company Profile

 
Read the Ind-Swift Labs company profile to learn more about the business and the management team. View IND Swift Laboratories Ltd facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

1496

Equity Type

ORD

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, and antineoplastic, as well as various products for ADHD symptoms. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company also exports its products. The company was incorporated in 1995 and is headquartered in Manimajra, India.

Contact Information

Address Shivalik Enclave SCO 850
NAC Manimajra, 160101
India
Phone 91 17 2506 1850
Fax 91 17 2273 0504

Top Executives

Name Age Since Title
Rishav Mehta 31 2010 Executive Director
Navrattan Munjal 70 1995 Chairman & MD
Himanshu Jain 40 2010 Joint MD & Whole Time Director
Sri Prakash Sharma 67 2012 Non-Executive Independent Director
Rajinder Kumar Gupta - 2021 Non-Executive Independent Director
Neerja Chathley - 2019 Non-Executive Independent Woman Director
Ashwani Kumar Vig 73 2020 Non-Executive Independent Director
Sahil Munjal 43 2020 President of Operations & Special Assignments and Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ISLB Price Commentary

Write your thoughts about IND Swift Laboratories Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Datta Medge
Datta Medge Jul 07, 2020 20:31
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy
atul singh
atul singh Jun 17, 2020 5:21
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email